PATENT CLAIM ANALYSIS

Application Number: 16065830
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["424", "452000"]

Abstract:
The present invention relates to a pharmaceutical composition comprising dutasteride and propylene glycol monolaurate, which improves the stability of dutasteride, which is a poorly soluble drug as a 5-alpha reductase inhibitor, and a process for its preparation. More particularly, the present invention also relates to a capsule formulation which is smaller in size than a commercial dutasteride capsule formulation (AVODART®), but has the equivalent dissolution rate by preparing a pharmaceutical composition comprising propylene glycol monolaurate and dutasteride, which can improve the stability of the dutasteride. A dutasteride formulation having enhanced patient's compliance and improved stability and a method for producing the same are provided.

Claim (Index 1):
A pharmaceutical composition comprising dutasteride of the following Formula (I) and propylene glycol monolaurate:

Metadata:
- Claim Count in Document: 20.0
- Percentile: 94.0
- Lexical Diversity: 1.73134
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15759137', '13617714', '10990118', '15204277', '13417686']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.695994206404469
- 35 USC 102 Novelty (BERT): 0.5241241939818468
- Combined Prediction Score: 0.6788072051622067
- Mean Citation Score: 199.906702
- Max Citation Score: 332.19662
- Similarity Product: 235.5672590577948

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test